February 4, 2022

IVD devices: Extension of timelines for the application of Regulation (EU) 2017/746

Regulation (EU) 2022/112 of the European Parliament and of the Council amending Regulation (EU) 2017/746 as regards transitional provisions for certain in vitro diagnostic medical devices and the deferred application of conditions for in-house devices was published on January 25, 2022.

The new regulation amended Articles 110, 112, and 113, providing new timelines for the implementation of Regulation (EU) 2017/746. In particular, the term of validity of any certificates issued under the directive has been extended from May 27, 2024 to May 27, 2025.

The European Commission explained that “the IVD Regulation will apply from 26 May 2022 as scheduled. However, there is a serious shortage of notified body capacity, making it impossible for manufacturers to conduct the legally required conformity assessment procedures in time. Without any legislative action, there was a risk of significant disruption in the supply of various essential in vitro diagnostic medical devices on the market, affecting the diagnosis of patients and their access to relevant health care.”

In particular, devices for which the conformity assessment procedure pursuant to Directive 98/79/EC did not require the involvement of a notified body, for which a declaration of conformity was drawn up prior to May 26, 2022, in accordance with that directive, and for which the conformity assessment procedure pursuant to this regulation requires the involvement of a notified body, may be placed on the market or put into service until the following dates:

(a) May 26, 2025, for class D devices (higher risk devices, such as HIV or hepatitis tests);

(b) May 26, 2026, for class C devices (lower risk devices, such as certain influenza tests); and

(c) May 26, 2027, for class B and class A sterile devices (lower risk devices).

In any event, it is further specified that (i) the requirements of the regulation relating to post-market surveillance, market surveillance, vigilance, and registration of economic operators and devices shall apply to these devices; and (ii) the notified body that issued the relevant certificates shall continue to be responsible for the appropriate surveillance with regard to all applicable requirements relating to the devices it has certified.

Moreover, the application of certain requirements for devices manufactured and used in the same health institution (known as “in-house devices”) has been deferred for two years until May 2024. If, however, a health institution can prove that an equivalent device is not available on the market, the transitional period will end in May 2028.

No change is proposed for CE-marked devices that do not require notified body involvement under the IVD regulation, or for “new” devices, i.e., devices that have neither a notified body certificate nor a declaration of conformity under the current Directive 98/79/EC. For those devices, the IVD regulation will apply as of May 26, 2022, as originally planned.

< Back to blog
Welcome to the Portolano Cavallo Life Sciences blog focusing on legal development and key legal issues affecting the Life Sciences-Healthcare industry.
Read more
Our highly-ranked team of professionals will provide news, insights and multidisciplinary commentary on the hottest and most recent regulatory, transactional and contentious aspects of the pharmaceutical, bio-tech, med-tech, food supplement and healthcare world with an eye on its digital transformation and technological developments.

This blog will be a place for focusing on digital health, telemedicine and artificial intelligence, as well as more traditional topics: from the protection of intellectual properties to performance of clinical trials, from the market access to advertising and competition issues, from internal and criminal investigations to M&A and Venture Capital transactions.

October 6, 2023
CBD products: the Administrative Court suspended until October 24 the recent Decree of the Italian Ministry of Health listing cannabidiol for oral use among narcotic drugs, due to the lack o...
October 4, 2023
The Guidelines for regulating contractual relations between universities and research institutes and private sponsors were adopted by the relevant Italian Ministries following the amendment ...
September 21, 2023
CBS products: from September 20th, compositions for oral administration of cannabidiol obtained from Cannabis sativa extracts shall be considered as narcotic drugs in Italy, as they have bee...
July 27, 2023
Payback on medical devices: Italian government announces extension of payment deadline to October 30, 2023
July 21, 2023
On July 21, 2023, the Italian Ministry of Health published new guidelines on health advertising of self-medication drugs (OTC) and non-prescription drugs (SOP), including advertising on new ...
Search by...
Follow us on
Follow us on